The Future of Amyloidosis Clinical Trials

Light chain amyloidosis often raises many questions, but there’s a growing sense of optimism. Our service connects you to the latest clinical trials, focusing specifically on advanced stages of light chain amyloidosis. We help patients find and join new medical studies, giving them access to cutting-edge options.

Compliance and Security Certifications

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.

Massive Bio has onboarded over 160,000 cancer patients to find their clinical trial

Our matching system connects you with the latest clinical trials, offering new hope for those battling light chain amyloidosis. You’ll discover comprehensive details on clinical trials for various stages of the disease. These trials offer innovative options not yet widely available, targeting the specific pathology associated with your amyloidosis diagnosis. This represents an opportunity for you to be proactive in managing the illness with our guidance and support.

We review your medical records and utilize our AI system to find clinical trials you can join. We also offer a concierge service to help you seamlessly transition into the clinical trial.

Our team of specialized nurses and physicians will ensure they take care of every detail of your participation in the trial, before, during, and after your enrollment.

All the services provided are completely free for you and your treating physician.

Light chain amyloidosis is a rare disease caused by an abnormal deposition of amyloid proteins in various organs and tissues. These proteins are derived from light chains, a component of antibodies produced by plasma cells. The disease can affect different organs, including the heart, kidneys, liver, spleen, and nervous system. Unlike cancer, light chain amyloidosis is not characterized by uncontrolled growth of cells but by the harmful effects of the amyloid deposits.

The staging of amyloidosis is an important aspect of understanding the extent of the disease and guiding treatment decisions. The staging is based on assessing the extent of organ involvement and the overall burden of the disease. It typically focuses on three major organ systems most commonly affected: the heart, kidneys, and liver. Here are the general stages used in AL amyloidosis:

Stage I (Early Stage Amyloidosis):

  • Minimal organ involvement.
  • Laboratory tests show only slightly abnormal levels of cardiac biomarkers (such as NT-proBNP, a marker for heart stress) and kidney function markers (like serum creatinine).
  • Patients in this stage may have fewer symptoms and a better prognosis.

Stage II (Intermediate Stage Amyloidosis):

  • Moderate organ involvement.
  • Laboratory tests show moderately elevated cardiac and kidney biomarkers.
  • Symptoms may be more pronounced, and the disease may affect daily activities.

Stage III (Advanced Stage Amyloidosis):

  • Significant organ involvement, especially of the heart and kidneys.
  • Laboratory tests reveal high levels of cardiac and renal biomarkers.
  • Symptoms are more severe and may include significant heart problems (like heart failure), kidney dysfunction (potentially requiring dialysis), and other organ complications.
  • Prognosis in this stage is more guarded, and aggressive treatment may be necessary.

Stage IV (Severe Stage Amyloidosis):

  • This stage is sometimes used to denote extremely severe organ involvement.
  • Markedly elevated biomarkers and profound symptoms.
  • Organ failure may be imminent or present, requiring intensive medical intervention.
  • The focus of treatment may shift towards managing symptoms and improving quality of life.

Options for light chain (AL) amyloidosis are tailored to each patient based on the extent of organ involvement, overall health, and specific characteristics of their disease. The primary goal is to reduce the production of abnormal light chains that form amyloid deposits. Here are the main options:

Chemotherapy: The use of chemotherapy drugs is a standard approach to treat AL amyloidosis.

Immunotherapy and Targeted Therapy: These options involve using medications that specifically target the abnormal cells or pathways in AL amyloidosis.

Clinical Trials: Participation in clinical trials can provide access to new and emerging therapies that are not yet widely available.

Next-Generation Sequencing (NGS) is utilized in the context of amyloidosis, but its application is somewhat different compared to its use in other diseases like cancer. In amyloidosis, NGS plays a role in several key areas:

1. Subtype Identification: Amyloidosis can be caused by various types of proteins. In light chain (AL) amyloidosis, the amyloid is formed from parts of antibodies known as light chains. NGS can be used to identify the specific light chain genes that are overproduced and to understand the clonality of plasma cells that produce these abnormal proteins.

2. Risk Stratification and Prognosis: NGS can help in determining the genetic changes in plasma cells that produce amyloid proteins. Certain genetic mutations are associated with prognosis and can guide treatment decisions.

3. Differentiating AL from Other Types of Amyloidosis: There are several types of amyloidosis, such as ATTR (transthyretin amyloidosis), which can be hereditary or acquired. NGS is useful in identifying mutations in the TTR gene in cases of hereditary ATTR amyloidosis. This is crucial for accurate diagnosis and appropriate treatment.

4. Personalized Treatment Approaches: In some instances, understanding the genetic makeup of the amyloid-producing cells can aid in tailoring more personalized treatment approaches, especially in the context of clinical trials.

5. Research and Discovery: NGS is a powerful tool in research for better understanding the pathogenesis of amyloidosis and for developing new therapeutic targets.

Clinical trials play a crucial role in the option of light chain amyloidosis for several reasons:

6. Access to New Options: Clinical trials offer patients a chance to try novel options that might be more effective, especially in cases where standard options are insufficient.

7. Improving Outcomes: Participating in clinical trials contributes to knowledge that could enhance survival rates and quality of life for future patients.

8. Comprehensive Care: Patients in clinical trials often receive high-level care and are closely monitored by a team of healthcare professionals and researchers.

9. Hope for the Future: For many patients, participating in a clinical trial provides hope—both for their own option and the possibility that their participation will aid future patients.

10. Advancing Research: These trials are essential for research, helping scientists understand how new options work and for whom they are most effective, leading to more efficient option strategies and personalized medicine.

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new treatments. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important treatment option for many cancer patients.

We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.

The Most Recent Advances in Amyloidosis Treatment Options

Our matching system connects you with the latest clinical trials, offering new hope for those battling light chain amyloidosis. You’ll discover comprehensive details on clinical trials for various stages of the disease. These trials offer innovative treatments not yet widely available, targeting the specific pathology associated with your amyloidosis diagnosis. This represents an opportunity for you to be proactive in managing the illness with our guidance and support.

How Our System Works

We review your medical records and utilize our AI system to find clinical trials you can join. We also offer a concierge service to help you seamlessly transition into the clinical trial.

Our team of specialized nurses and physicians will ensure they take care of every detail of your participation in the trial, before, during, and after your enrollment.

All the services provided are completely free for you and your treating physician.

Understanding the Disease

What is Light Chain Amyloidosis?

Light chain amyloidosis is a rare disease caused by an abnormal deposition of amyloid proteins in various organs and tissues. These proteins are derived from light chains, a component of antibodies produced by plasma cells. The disease can affect different organs, including the heart, kidneys, liver, spleen, and nervous system. Unlike cancer, light chain amyloidosis is not characterized by uncontrolled growth of cells but by the harmful effects of the amyloid deposits.

The staging of amyloidosis is an important aspect of understanding the extent of the disease and guiding treatment decisions. The staging is based on assessing the extent of organ involvement and the overall burden of the disease. It typically focuses on three major organ systems most commonly affected: the heart, kidneys, and liver. Here are the general stages used in AL amyloidosis:

Stage I (Early Stage Amyloidosis):

Minimal organ involvement.

Laboratory tests show only slightly abnormal levels of cardiac biomarkers (such as NT-proBNP, a marker for heart stress) and kidney function markers (like serum creatinine).

Patients in this stage may have fewer symptoms and a better prognosis.

Stage II (Intermediate Stage Amyloidosis):

Moderate organ involvement.

Laboratory tests show moderately elevated cardiac and kidney biomarkers.

Symptoms may be more pronounced, and the disease may affect daily activities.

Stage III (Advanced Stage Amyloidosis):

Significant organ involvement, especially of the heart and kidneys.

Laboratory tests reveal high levels of cardiac and renal biomarkers.

Symptoms are more severe and may include significant heart problems (like heart failure), kidney dysfunction (potentially requiring dialysis), and other organ complications.

Prognosis in this stage is more guarded, and aggressive treatment may be necessary.

Stage IV (Severe Stage Amyloidosis):

This stage is sometimes used to denote extremely severe organ involvement.

Markedly elevated biomarkers and profound symptoms.

Organ failure may be imminent or present, requiring intensive medical intervention.

The focus of treatment may shift towards managing symptoms and improving quality of life.

What are the Treatment Options for Amyloidosis?

Treatment options for light chain (AL) amyloidosis are tailored to each patient based on the extent of organ involvement, overall health, and specific characteristics of their disease. The primary goal is to reduce the production of abnormal light chains that form amyloid deposits. Here are the main treatment options:

Chemotherapy:

The use of chemotherapy drugs is a standard approach to treat AL amyloidosis.

Immunotherapy and Targeted Therapy:

These treatments involve using medications that specifically target the abnormal cells or pathways in AL amyloidosis.

Clinical Trials:

Participation in clinical trials can provide access to new and emerging therapies that are not yet widely available.

NGS Testing and Amyloidosis

Next-Generation Sequencing (NGS) is utilized in the context of amyloidosis, but its application is somewhat different compared to its use in other diseases like cancer. In amyloidosis, NGS plays a role in several key areas:

1. Subtype Identification: Amyloidosis can be caused by various types of proteins. In light chain (AL) amyloidosis, the amyloid is formed from parts of antibodies known as light chains. NGS can be used to identify the specific light chain genes that are overproduced and to understand the clonality of plasma cells that produce these abnormal proteins.

2. Risk Stratification and Prognosis: NGS can help in determining the genetic changes in plasma cells that produce amyloid proteins. Certain genetic mutations are associated with prognosis and can guide treatment decisions.

3. Differentiating AL from Other Types of Amyloidosis: There are several types of amyloidosis, such as ATTR (transthyretin amyloidosis), which can be hereditary or acquired. NGS is useful in identifying mutations in the TTR gene in cases of hereditary ATTR amyloidosis. This is crucial for accurate diagnosis and appropriate treatment.

4. Personalized Treatment Approaches: In some instances, understanding the genetic makeup of the amyloid-producing cells can aid in tailoring more personalized treatment approaches, especially in the context of clinical trials.

5. Research and Discovery: NGS is a powerful tool in research for better understanding the pathogenesis of amyloidosis and for developing new therapeutic targets.

The Role of Amyloidosis Clinical Trials

Clinical trials play a crucial role in the treatment of light chain amyloidosis for several reasons:

6. Access to New Treatments: Clinical trials offer patients a chance to try novel treatments that might be more effective, especially in cases where standard treatments are insufficient.

7. Improving Outcomes: Participating in clinical trials contributes to knowledge that could enhance survival rates and quality of life for future patients.

8. Comprehensive Care: Patients in clinical trials often receive high-level care and are closely monitored by a team of healthcare professionals and researchers.

9. Hope for the Future: For many patients, participating in a clinical trial provides hope—both for their own treatment and the possibility that their participation will aid future patients.

10. Advancing Research: These trials are essential for research, helping scientists understand how new treatments work and for whom they are most effective, leading to more efficient treatment strategies and personalized medicine.

Dr. Arturo explains:

What Are Clinical Trials?

Cancer is an unfortunate reality that touches most of us at some point in our lives. If you or a loved one has cancer, you may have heard or read that clinical trials could offer access to innovative new options. But what exactly is a clinical trial? In this video, Massive Bio co-founder Arturo Loaiza-Bonilla, MD, explains how clinical trials work, what to expect if you enroll in one, and why a clinical trial can be an important option for many cancer patients.

We dream of the day when cancer disappears from our lives. Massive Bio is working tirelessly on achieving that goal.

An amyloidosis clinical trial may be an option for you
1
Consent Signed

Fill out our contact form and sign our consent form

2
Data Collection

We collect your medical records securely

3
Pre Screening

Our expert nurses check clinical trials and contact you

4
Concierge Services

We support you with appointments, travel, and accommodation

Let’s explore your options and bring new hope to your journey.

We offer a quick, easy and FREE way to find amyloidosis clinical research opportunities for patients like you. With our unique clinical trial matching system (CTMS) and team specialized in oncology, we can rapidly match you to a clinical research study for those diagnosed with amyloidosis.

[EN] Ads Landing Pages - United States & Canada - English
Let's Explore Your Options
By filling out this form, you're consenting only to release your medical records. You're not agreeing to participate in clinical trials yet.
Frequently asked questions

To enroll in clinical trial, you must meet highly specific criteria that’s established by the researchers who are conducting the investigation. That includes detailed information about type of cancer, treatment history, response to treatment, and other data that is collected in medical records.

If you are being treated for cancer or any other disease, your doctor should have a complete record of your medical care, including specific information about what form of the disease you have and what treatments you have received. Your patient relations coordinator will contact you and inform you about the details.

Massive Bio provides its services to the patients and their doctors at no cost—you won’t have to pay anything to receive a clinical-research matching report. There are no hidden costs involved.

Massive Bio strictly adheres to all HIPAA guidelines and international regulations focused on maintaining your privacy. We take extra measures to secure your personal information, ensuring it is protected beyond the mandatory requirements.

Your doctor may know of a clinical research study being conducted in your area that’s recruiting participants and is right for you. However, Massive Bio uses its artificial intelligence powered platform to match patients to clinical research studies that give you the best chance of a positive outcome and are being conducted in a geographical location that makes sense for you.

Yes, Massive Bio keeps your doctor up to date on your status throughout your participation.